SEC 13F Intelligence

Managers / Q4 2022 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$168M
Q4 2022
Positions
105
Filings on Record
30
2019–present window
Filed
Feb 14, 2023
original filing

Summary

Highvista Strategies LLC reported $168M in U.S.-listed holdings across 105 positions for Q4 2022.

Its largest position, DELL, represents 8.5% of the portfolio.

Compared with Q3 2022, the fund opened 26 new positions and exited 34.

Portfolio Metrics

Turnover
+22.9%
vs prior filed quarter
Top-10 Concentration
+40.7%
share of reported value
Largest Position
+8.5%
Dell Technologies
New / Exited
26 / 34
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 81.6%Other: 10.4%ADR: 5.3%ETP: 2.8%
  • Common Stock · 81.6% · $137M
  • Other · 10.4% · $17M
  • ADR · 5.3% · $9M
  • ETP · 2.8% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SJIEURSOUTH JERSEY INDS INCNEW+79.5K79.5K+$3M$3M
VRNAVERONA PHARMA PLCNEW+68.7K68.7K+$2M$2M
DICE THERAPEUTICS INCNEW+39.1K39.1K+$1M$1M
VTYXUSDVENTYX BIOSCIENCES INCNEW+33.3K33.3K+$1M$1M
RYTMRHYTHM PHARMACEUTICALS INCNEW+35.5K35.5K+$1M$1M
AKROAKERO THERAPEUTICS INCNEW+18.6K18.6K+$1M$1M
KROSKEROS THERAPEUTICS INCNEW+18.6K18.6K+$893,940$893,940
PROTHENA CORP PLCNEW+14.6K14.6K+$877,963$877,963

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C8.49%$14M355.4K
2MAMASTERCARD INCORPORATEDhistory →CL A7.68%$13M37.2K
3VVISA INChistory →COM CL A5.24%$9M42.5K
4FISVFISERV INChistory →COM5.16%$9M85.9K
5MSD ACQUISITION CORPUNIT 03/25/20263.00%$5M500.0K
6AXSMAXSOME THERAPEUTICS INChistory →COM2.52%$4M55.1K
7CPNGCOUPANG INChistory →CL A2.24%$4M256.3K
8PYPLPAYPAL HLDGS INChistory →COM2.22%$4M52.6K
9ISHARES TRRUS 1000 VAL ETF2.14%$4M23.8K
10FT2FIRST HORIZON CORPORATIONhistory →COM1.97%$3M135.4K
11ATVIEURACTIVISION BLIZZARD INChistory →COM1.82%$3M40.0K
12TGNATEGNA INChistory →COM1.81%$3M144.0K
13ACRSACLARIS THERAPEUTICS INChistory →COM1.75%$3M187.6K
14VRDNVIRIDIAN THERAPEUTICS INChistory →COM1.73%$3M100.0K
15VMWEURVMWARE INChistory →CL A COM1.72%$3M23.6K
16SJIEURSOUTH JERSEY INDS INChistory →COM1.68%$3M79.5K
17BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.62%$3M92.4K
18RLAYRELAY THERAPEUTICS INChistory →COM1.57%$3M176.5K
19BKIEURBLACK KNIGHT INChistory →COM1.55%$3M42.2K
20TVTXTRAVERE THERAPEUTICS INChistory →COM1.52%$3M121.8K
21CYMABAY THERAPEUTICS INCCOM1.47%$2M395.3K
22RPTXREPARE THERAPEUTICS INChistory →COM1.44%$2M164.9K
23COGTCOGENT BIOSCIENCES INChistory →COM1.26%$2M184.0K
24PROMETHEUS BIOSCIENCES INCCOM1.26%$2M19.3K
25OPHTEURIVERIC BIO INChistory →COM1.25%$2M98.1K
26NOVOCURE LTDORD SHS1.22%$2M28.0K
27KURAKURA ONCOLOGY INChistory →COM1.21%$2M164.1K
28APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.20%$2M39.1K
29CATALYST PARTNRS ACQUISITN CUNIT 99/99/99991.19%$2M200.0K
30VRNAVERONA PHARMA PLChistory →SPONSORED ADS1.07%$2M68.7K
31CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.02%$2M93.9K
32EWTXEDGEWISE THERAPEUTICS INCCOM0.99%$2M187.5K
33RCUSARCUS BIOSCIENCES INCCOM0.88%$1M71.7K
34CHINOOK THERAPEUTICS INCCOM0.77%$1M49.5K
35BMEABIOMEA FUSION INCCOM0.72%$1M144.7K
36DICE THERAPEUTICS INCCOM0.72%$1M39.1K
37DYNDYNE THERAPEUTICS INCCOM0.70%$1M102.4K
38TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.65%$1M24.7K
39VTYXUSDVENTYX BIOSCIENCES INCCOM0.65%$1M33.3K
40DBCINVESCO DB COMMDY INDX TRCKUNIT0.62%$1M42.4K
41RYTMRHYTHM PHARMACEUTICALS INCCOM0.61%$1M35.5K
42AKROAKERO THERAPEUTICS INCCOM0.61%$1M18.6K
43BMRNBIOMARIN PHARMACEUTICAL INCCOM0.60%$1M9.7K
44SRPTSAREPTA THERAPEUTICS INCCOM0.59%$999,4517.7K
45XENEXENON PHARMACEUTICALS INCCOM0.59%$999,15625.3K
46ALNYALNYLAM PHARMACEUTICALS INCCOM0.57%$963,9084.1K
47AM6AMICUS THERAPEUTICS INCCOM0.56%$944,00477.3K
48PCVXVAXCYTE INCCOM0.56%$940,10819.6K
49GALAPAGOS NVSPON ADR0.55%$918,71020.7K
50SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.54%$905,22634.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.